{"schema_version":"1.0","type":"article","title":"GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.md","lang":"zh-Hant","date":"2026-07-08","publish_at":"2026-07-08T09:10:35+08:00","updated_at":"2026-07-08","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","dorzagliatin","多格列艾汀","glucokinase activator","GKA","代謝疾病","糖尿病","MASH","臨床數據","慢病管理","API / CDMO","台灣生技","生技投資","製藥巨頭"],"summary":"GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。","key_points":[],"facts":[],"sections":["01｜GLP-1 已經證明有效，但真實世界的問題是長期依從性","02｜dorzagliatin 的定位，不是普通降糖藥，而是血糖感測器修復","03｜dorzagliatin 加 GLP-1 的真正想像：少一點副作用，多一點可持續性","04｜代謝藥物正在從單點治療，走向聯用矩陣","05｜台灣投資人可以看什麼：不要硬追 GLP-1，先看代謝藥物分工","06｜結語：減重藥戰爭的下一題，是讓療效留得住"],"references":[{"title":"Nature Medicine, [Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial](), 2022.","source":"","date":"","url":"https://www.nature.com/articles/s41591-022-01802-6"},{"title":"Nature Medicine, [Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial](), 2022.","source":"","date":"","url":"https://www.nature.com/articles/s41591-022-01803-5"},{"title":"BMJ, [Weight regain after cessation of medication for weight management: systematic review and meta-analysis](), 2026.","source":"","date":"","url":"https://www.bmj.com/content/392/bmj-2025-085304"},{"title":"FDA, [FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease](), 2024.","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease"},{"title":"New England Journal of Medicine, [Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis](), 2024.","source":"","date":"","url":"https://www.nejm.org/doi/10.1056/NEJMoa2401943"}],"images":[{"alt":"Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 1）","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-01.png"},{"alt":"Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 2）","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-02.png"},{"alt":"Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 3）","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-03.png"},{"alt":"Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 4）","url":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-08）。GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住。https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}